NovelStem International Corp. 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission file number: 000-22908 NOVELSTEM INTERNATIONAL CORP. (Exact name of registrant as specified in its charter) Florida 65-0385686 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 2255 Glades Road , Suite 221A , Boca Raton , FL 33431 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code ( 410 ) 654-3315 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered None Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filed, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer  ☒ Smaller reporting company   ☒ Emerging growth company   ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. Class Outstanding at May 12, 2023 Common Stock, $0.01 par value per share 46,881,475 NOVELSTEM INTERNATIONAL CORP. Quarterly Report on Form 10-Q for the Quarterly Period Ended March 31, 2023 TABLE OF CONTENTS PAGE Part I Financial Information Item 1. Unaudited Condensed Financial Statements: Condensed Balance Sheets as of March 31, 2023 and December 31, 2022 3 Condensed Statements of Operations for the three months ended March 31, 2023 and 2022 4 Condensed Statements of Changes in Shareholders’ Equity for the three months ended March 31, 2023 and 2022 5 Condensed Statements of Cash Flows for the three months ended March 31, 2023 and 2022 6 Notes to Condensed Financial Statements 7 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3. Quantitative and Qualitative Disclosures About Market Risk 17 Item 4. Controls and Procedures 17 Part II Other Information Item 1. Legal Proceedings 17 Item 1A. Risk Factors 17 Item 6. Exhibits 17 Signatures 18 2 PART I ITEM 1. UNAUDITED CONDENSED FINANCIAL STATEMENTS NOVELSTEM INTERNATIONAL CORP. CONDENSED BALANCE SHEETS 2023 2022 As of March 31, December 31, 2023 2022 (Unaudited) ASSETS Current assets: Cash $ 40,562 $ 6,346 Accounts receivable, administrative fees - 12,000 Prepaid expenses 39,567 40,561 Total current assets 80,129 58,907 Investment in Netco Partners 137,011 137,011 Investment in NewStem Ltd 1,985,695 2,090,286 Total assets $ 2,202,835 $ 2,286,204 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable $ 128,499 $ 21,203 Current portion of long-term note payable 357,529 - Accrued expenses 37,673 43,673 Total current liabilities 523,701 64,876 Long-term note payable, including accrued interest - 288,450 Total liabilities 523,701 353,326 Commitments and contingencies (see Note 7) - Shareholders’ equity: Common stock, $ .01 par value, 100,000,000 shares authorized, 50,316,672 shares issued, and 46,881,475 shares outstanding as of March 31, 2023 and December 31, 2022 468,815 468,815 Additional paid-in capital 290,619,404 290,604,327 Accumulated deficit ( 289,209,331 ) ( 288,940,510 ) Treasury stock, at cost, 3,435,197 shares as of March 31, 2023 and December 31, 2022 ( 199,754 ) ( 199,754 ) Treasury stock, at cost, 3,435,197 shares as of March 31, 2023 and December 31, 2022 ( 199,754 ) ( 199,754 ) Total shareholders’ equity 1,679,134 1,932,878 Total liabilities and shareholders’ equity $ 2,202,835 $ 2,286,204 The accompanying notes are an integral part of these condensed financial statements. 3 NOVELSTEM INTERNATIONAL CORP. CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) 2023 2022 Three Months Ended March 31, 2023 2022 Operating expenses: General and administrative expenses $ 164,792 $ 138,956 Contra expenses - legal fees and administrative costs (Note 8) - ( 310,000 ) Total operating expenses 164,792 ( 171,044 ) Loss from operations ( 164,792 ) 171,044 Interest expense 7,313 1,605 Loss before income taxes ( 172,105 ) 169,439 Provision for income tax - - Loss before equity in net income of equity method investees ( 172,105 ) 169,439 Equity in net loss of equity method investees ( 96,716 ) ( 386,903 ) Net loss $ ( 268,821 ) $ ( 217,464 ) Basic and diluted net loss per share: Net loss per share - basic and diluted $ ( 0.01 ) $ - Weighted average number of shares outstanding - basic and diluted 46,881,475 46,881,475 The accompanying notes are an integral part of these unaudited condensed financial statements. 4 NOVELSTEM INTERNATIONAL CORP. CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED) For the Three Months Ended March 31, 2023: Shares Stock Capital Deficit Shares Stock Equity Additional Number of Total Number of Common Paid-In Accumulated Treasury Treasury Shareholders’ Shares Stock Capital Deficit Shares Stock Equity Balance, January 1, 2023 46,881,475 $ 468,815 $ 290,604,327 $ ( 288,940,510 ) 3,435,197 $ ( 199,754 ) $ 1,932,878 Net loss - - - ( 268,821 ) - - ( 268,821 ) Stock option compensation - - 15,077 - - - 15,077 Balance, March 31, 2023 46,881,475 $ 468,815 $ 290,619,404 $ ( 289,209,331 ) 3,435,197 $ ( 199,754 ) $ 1,679,134 For the Three Months Ended March 31, 2022: Additional Number of Total Number of Common Paid-In Accumulated Treasury Treasury Shareholders’ Shares Stock Capital Deficit Shares Stock Equity Balance, January 1, 2022 46,881,475 $ 468,815 $ 290,321,665 $ ( 288,174,780 ) 3,435,197 $ ( 199,754 ) $ 2,415,946 Net loss - - - ( 217,464 ) - - ( 217,464 ) Stock option compensation - - 49,011 - - - 49,011 Balance, March 31, 2022 46,881,475 $ 468,815 $ 290,370,676 $ ( 288,392,244 ) 3,435,197 $ ( 199,754 ) $ 2,247,493 The accompanying notes are an integral part of these condensed financial statements. 5 NOVELSTEM INTERNATIONAL CORP. CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) 2023 2022 Three Months Ended March 31, 2023 2022 Cash flows from operating activities: Net loss $ ( 268,821 ) $ ( 217,464 ) Equity in loss of equity method investees 96,716 386,903 Distribution from NetCo Partners 7,875 - Accrued interest added to long-term note payable 7,079 - Stock-based compensation 15,077 49,011 Change in operating assets and liabilities: Accounts receivable, administrative fees 12,000 - Prepaid expenses 994 ( 1,045 ) Accounts payable 107,296 ( 17,549 ) Accrued expenses ( 6,000 ) ( 5,752 ) Net cash from operating activities ( 27,784 ) 194,104 Cash flows from financing activities: Repayment of short term note payable $ - $ ( 100,000 ) Proceeds from long term notes payable 62,000 - Net cash from financing activities 62,000 ( 100,000 ) Net change in cash 34,216 94,104 Cash at the beginning of the period 6,346 8,666 Cash at the end of the period $ 40,562 $ 102,770 Supplemental cash flow information: Cash paid during the period for: Interest $ 234 $ 7,357 The accompanying notes are an integral part of these condensed financial statements. 6 NOVELSTEM INTERNATIONAL CORP. NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) NOTE 1— NATURE OF OPERATIONS Description of Business NovelStem International Corp. (“NovelStem” or the “Company”) is a holding company whose principal assets are a 30.58 % equity interest in NewStem Ltd, an Israeli biotech company (“NewStem”), and a 50 % equity interest in NetCo Partners (“NetCo”). NovelStem was formerly known as Hollywood Media Corp. The Company was incorporated in the State of Florida on January 22, 1993 and changed its name to NovelStem International Corp. in September 2018 as a result of its business focus shift from a media business to biotech. NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is collaborating with life sciences companies for the development of drugs and reagents. NetCo is a legacy media business interest which owns “Net Force”, a book publishing franchise. Liquidity and Management’s Plans Since inception, the Company has accumulated a deficit of approximately $ 289,000,000 . The accumulated deficit of the Company subsequent to its business focus shift and name change in September 2018 is approximately $ 2,500,000 which is comprised primarily of allocated losses from equity method investments and general and administrative costs incurred by the Company. The Company will need to obtain additional funds to continue its operations. Management’s plans with regard to these matters include additional financing and fundraising until its equity investment in NewStem is profitable. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStem will become profitable. The Company has in place a financing agreement with related parties to borrow up to $ 600,000 for working capital needs (see Note 4). Additionally, in May 2023, the Company entered into a financing agreement with a shareholder to borrow $ 300,000 consisting of advances of $ 150,000 in May 2023 and $ 150,000 in October 2023 (see Note 9). Following this financing, the Company believes that its cash resources are sufficient for the operations of the next twelve months. NOTE 2— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited condensed financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed financial statements have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 31, 2023, from which the Company derived the balance sheet data at December 31, 2022. 7 Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations for interim reporting. The Company believes that the disclosures contained herein are adequate to make the information presented not misleading. These condensed financial statements should be read in conjunction with the Company’s Form 10K filed with the Securities and Exchange Commission on March 31, 2023 for the years ended December 31, 2022 and 2021. Equity Investments Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an investee depends on an evaluation of several factors, including, among others, representation on the investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company . Under the equity method of accounting, an investee company’s accounts are not reflected within the Company’s balance sheets or statements of operations; however, the Company’s share of the earnings or losses of the investee company is reflected in the caption “Equity in net income (loss) of investee company” in the statements of operations. The Company’s carrying value in an equity method investee company is reflected in the caption “Investment in investee company’ in the Company’s balance sheets. The Company reviews equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable. The Company holds a minority investment in an entity, NewStem, which is accounted for pursuant to the equity method of accounting. Additionally, the Company is a 50 % partner in NetCo (which is accounted for pursuant to the equity method of accounting). See Note 3. Basic and Diluted Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding during the period, excluding treasury stock. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding plus the dilutive potential of common shares which would result from the exercise of stock options and warrants. The dilutive effects of stock options and warrants are excluded from the computation of diluted net income (loss) per share if the effect of doing so would be antidilutive. The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited): SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE 2023 2022 Three Months Ended March 31, 2023 2022 Net loss available to common shareholders $ ( 268,821 ) $ ( 217,464 ) Weighted average shares outstanding: -Basic 46,881,475 46,881,475 Add: Warrants - - Add: Stock options - - -Diluted 46,881,475 46,881,475 Basic and diluted net loss per share $ ( 0.01 ) $ - 8 Warrants and stock options excluded from the above calculations are as follows: SCHEDULE OF WARRANTS AND STOCK OPTIONS Three Months Ended March 31, 2023 2022 Warrants 3,000,000 3,000,000 Stock options 5,760,000 5,400,000 NOTE 3— EQUITY METHOD INVESTMENTS Investment in NewStem In 2018, the Company entered into a Share Purchase Agreement with NewStem and other related parties to provide aggregate funding of up to $ 4,000,000 to NewStem. This funding was to be provided through the sale of up to 50,000 common shares of NewStem to the Company representing 33 % of New Stem’s outstanding shares. In 2018, the Company purchased 25,000 shares of NewStem for $ 2,000,000 acquiring an ownership interest of 20 %. The Company made additional investments in 2019 and 2020 purchasing 12,500 shares each year for a $ 1,000,000 investment each year. NewStem sold and issued shares to third party investors in 2021 and 2022 resulting in the Company recognizing a gain on dilution of equity method investment. These transactions resulted in the Company having an ownership interest of 30.58 % as of March 31, 2023 and December 31, 2022. The Company accounts for its investment in NewStem under the equity method. At March 31, 2023 and December 31, 2022, the carrying value of the investment in NewStem exceeded the underlying net assets of NewStem by $ 1,985,695 and $ 2,090,286 , respectively. The excess relates to identified intangible assets including license agreements, specialized work force (goodwill) and two separate projects of in process research and development (“IPR&D”) related to stem cell-based diagnostics and therapeutics for cancer chemotherapies. The Company assesses its investment in NewStem for impairment on an annual basis. NewStem is in the development stage and has incurred losses since its inception and has yet to generate any revenues. NewStem will need to obtain additional funds to continue its operations. NewStem management’s plans with regard to these matters include continued development, marketing, and licensing of its products, as well as seeking additional financing arrangements. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from sales of products or financing on terms acceptable to the Company. NewStem obtained additional funding of approximately $ 1,450,000 in 2022 through the sale of shares of ordinary stock. The following table represents the Company’s investment in NewStem: SCHEDULE OF INVESTMENTS Three Months Ended March 31, 2023 Year Ended December 31, 2022 (Unaudited) Investment in NewStem, beginning $ 2,090,286 $ 2,435,155 Allocation of net loss from NewStem, Ltd. ( 104,591 ) ( 732,393 ) Gain on dilution of equity method investment - 387,524 Investment in NewStem, ending $ 1,985,695 $ 2,090,286 9 The results of operations of the Company’s investment in NewStem is summarized below (unaudited): SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT 2023 2022 Three Months Ended March 31, 2023 2022 Condensed income statement information: Net revenues $ 95,000 $ - Gross margin $ 84,000 $ - Net loss $ ( 342,000 ) $ ( 1,228,000 ) Company’s allocation of net loss from NewStem, Ltd. $ ( 104,591 ) $ ( 386,903 ) The financial position of the Company’s investment in NewStem is summarized below: Three Months Ended March 31, 2023 Year Ended December 31, 2022 (Unaudited) Condensed balance sheet information: Current assets $ 679,000 $ 911,000 Non-current assets $ 19,000 $ 23,000 Current liabilities $ 122,000 $ 97,000 Non-current liabilities $ 124,000 $ 121,000 Investment in NetCo NovelStem owns a 50 % interest in NetCo, a joint venture that owns the Net Force publishing franchise. The Company accounts for its investment in NetCo under the equity method and recognizes nominal royalties from this arrangement. The Company assesses its investment in NetCo for impairment on an annual basis. The following table represents the Company’s investment in NetCo: SCHEDULE OF INVESTMENTS Three Months Ended March 31, 2023 Year Ended December 31, 2022 (Unaudited) Investment in NetCo, beginning $ 137,011 $ 137,011 Allocation of net income from Netco 7,875 12,591 Distribution from NetCo ( 7,875 ) ( 12,591 ) Investment in NetCo, ending $ 137,011 $ 137,011 10 The results of operations of the Company’s investment in NetCo is summarized below (unaudited): SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT 2023 2022 Three Months Ended March 31, 2023 2022 Condensed income statement information: Net sales $ 15,750 $ - Gross margin $ 15,750 $ - Net income $ 15,750 $ - Net income (loss) $ 15,750 $ - Company’s allocation of net income from NetCo $ 7,875 $ - The financial position of the Company’s investment in NetCo is summarized below: Three Months Ended March 31, 2023 Year Ended December 31, 2022 (Unaudited) Condensed balance sheet information: Current assets $ 13,475 $ 13,475 Non-current assets $ 272,799 $ 272,799 Current liabilities $ 12,252 $ 12,252 Non-current liabilities $ - $ - NOTE 4— NOTES PAYABLE RELATED PARTIES On April 12, 2021, the Company entered into a promissory note (the “Note”) with a related party (individual) for $ 100,000 . The Note accrued interest at 8 % per annum and matured on April 12, 2022 . The proceeds of this Note were used to pay operating expenses of the Company. Interest expense related to this Note was $ 1,198 for the three months ended March 31, 2022. The Note and accrued interest of $ 6,752 were paid in full on February 16, 2022. In May 2022, the Company entered into long-term notes payable in the form of finance agreements (the “Agreements”) with two individuals who are related parties, which were amended in July 2022, to borrow up to $ 600,000 for working capital needs. One of the individuals is a director and shareholder, the other is our Executive Chairman who is also a shareholder. These agreements provide for funding through January 31, 2024, provide for interest at a rate of 8 % per annum through November 11, 2022, at which time the interest rate increased to 10 % per annum for subsequent advances. The Agreements mature the earlier of January 31, 2024 or twenty months from the date of the first funded amount (May 2022) unless the shareholders agree to extend the due date at that time. The Company received advances of $ 342,000 and $ 280,000 , respectively, pursuant to this agreement through March 31, 2023 and December 31, 2022. Interest expense related to the agreements was $ 7,079 and $ 8,450 , respectively, for the three months ended March 31, 2023 and the year ended December 31, 2022. Pursuant to the Agreements, accrued interest is added to the note balances. 11 NOTE 5— EQUITY (a) General At March 31, 2023 and December 31, 2022, the Company had issued and outstanding 46,881,475 shares of its common stock, par value $ 0.01 per share. Holders of outstanding common stock are entitled to receive dividends when, as and if declared by the Board and to share ratably in the assets of the Company legally available for distribution in the event of a liquidation, dissolution or winding up of the Company. (b) Summary Employee Option Information The Company’s stock option plan provides for the grant to officers, directors, third party contractors and other future key employees of options to purchase shares of common stock. The purchase price may be paid in cash or, if the option is “in-the-money”, it is automatically exercised “net”. In a net exercise of an option, the Company does not require a payment of the exercise price of the option from the optionee but reduces the number of shares of common stock issued upon the exercise of the option by the smallest number of whole shares that has an aggregate fair market value equal to or in excess of the aggregate exercise price for the option shares covered by the option exercised. Each option is exercisable to one share of the Company’s common stock. Most options expire within six years from the date of the grant and generally vest on the first anniversary date of their issuance. Pursuant to the Equity Incentive Plan the Company’s board of directors approved on November 12, 2018, an aggregate of 5,760,000 options have been issued to directors and investor relations professionals. The Company utilized the Black-Scholes option-pricing model to estimate fair value, utilizing the following assumptions for the respective periods (all in weighted averages): SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS Three Months Ended March 31, 2023 2022 Risk-free interest rate 3.5 % 1.5 % Expected term of options, in years 4.0 3.9 Expected annual volatility 191.1 % 185.8 % Expected dividend yield 0 % 0 % Determined weighted average grant date fair value per option $ 0.19 $ 0.27 The expected term of the options represents an estimate of the length of time until the expected date of exercising the options. Options granted have a maximum life of 7 years. With respect to determining expected exercise behavior, the Company has grouped its option grants into certain groups to track exercise behavior and establish historical rates. The Company estimated volatility by considering historical stock volatility over the expected term of the option. The risk-free interest rates are based on the U.S. Treasury yields for a period consistent with the expected term. The dividend yield of 0 % is based on the Company’s history and expectation of dividend payout. The Company has not paid and does not anticipate paying dividends in the near future. 12 (c) Summary Option Information A summary of the Company’s option plans for the three months ended March 31, 2023, is presented below (unaudited): SCHEDULE OF STOCK OPTION ACTIVITIES Number Weighted of Average Options Exercise (in shares) Price Outstanding, December 31, 2022 5,400,000 $ 0.14 Granted 360,000 0.20 Outstanding, March 31, 2023 5,760,000 $ 0.14 Exercisable, March 31, 2023 5,400,000 $ 0.14 Stock-based compensation expense was approximately $ 15,000 and $ 49,000 in the three months ended March 31, 2023 and 2022, respectively. The total compensation cost related to non-vested awards not yet recognized was approximately $ 67,000 as of March 31, 2023. As of March 31, 2023, 360,000 options were unvested. These options vest one year from their grant date which is March 2024. (d) Warrants The Company has issued warrants at exercise prices equal to or greater than the market value of the Company’s common stock at the date of issuance. A summary of warrant activity follows (unaudited): SUMMARY OF WARRANTS ACTIVITY Number of Weighted shares Average underlying Exercise warrants Price Outstanding, December 31, 2022 3,000,000 $ 0.12 Granted - - Exercised - - Forfeited or expired - - Outstanding, March 31, 2023 3,000,000 $ 0.12 The warrants outstanding at March 31, 2023 have a weighted average remaining contractual life of approximately three months. 13 NOTE 6— INCOME TAXES The Company’s income tax provision differs from the expense that would result from applying statutory rates to income (loss) before taxes. A reconciliation of the provision (benefit) for income taxes with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows (unaudited): SCHEDULE OF INCOME BEFORE INCOME TAX 2023 2022 Three Months Ended March 31, 2023 2022 Computed tax at the federal statutory rate of 21 % $ ( 56,452 ) $ ( 45,668 ) State income taxes, net of federal income tax benefit ( 11,680 ) ( 9,449 ) Change in federal valuation allowance 87,972 117,021 Foreign rate differential ( 19,840 ) ( 61,904 ) Total provision for income tax $ - $ - NOTE 7— COMMITMENTS AND CONTINGENCIES The Company is the claimant in an arbitration proceeding against their 50 % partner in NetCo. The Company initiated the arbitration proceeding in an effort to maximize the total potential value to be derived from fully utilizing the NetCo intellectual property across publishing, entertainment, digital media, merchandising and other ancillary markets. Arbitration hearings were held at the end of July 2022. Arbitration proceedings for the joint owners of NetCo concluded during 2022 with final briefs being filed in January 2023. In a hearing on May 9, 2023, the arbitrator ordered all parties to submit additional briefings by May 30, 2023. At this time, the arbitrator indicated that a decision will be rendered within 30 days of receiving these final briefs. NOTE 8— LITIGATION FUNDING AGREEMENT On February 11, 2022, the Company entered into a nonrecourse litigation funding agreement (the “Agreement”) with Omni Bridgeway (Fund 4) Invt. 3 L.P. (“Omni”) related to an ongoing arbitration proceeding disclosed in Note 7. The Agreement provides for Omni to fund all costs related to the arbitration up to $ 1,000,000 in exchange for an assignment of a certain portion of rights to and interest in claims related to this arbitration. The agreement provides for specific calculations of the portion of any claims collected to be received by Omni with the remainder collectible by the Company. During the three months ended March 31, 2022, the Company received $ 310,000 pursuant to this agreement for the reimbursement of legal costs and working capital expenditures, including previously incurred general and administrative costs. NOTE 9— SUBSEQUENT EVENTS As disclosed in Note 1, on May 5, 2023 the Company entered into a financing agreement with a shareholder to borrow $ 300,000 consisting of advances of $ 150,000 in May 2023 and $ 150,000 in October 2023. This agreement bears no interest and matures May 5, 2025. In relation to the agreement, the Company has guaranteed that the shareholder’s separate equity investment in NewStem will have a minimum value of $ 650,000 at maturity of the agreement. Subsequent to the date on these financial statements, on May 11, 2023, the Company’s board of directors approved the amendment of outstanding warrant agreements to extend the expiration date from June 28, 2023 to June 28, 2025. 14 NOVELSTEM INTERNATIONAL CORP. ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Statements in the following discussion and throughout this Form 10-Q that are not historical in nature are “forward-looking statements.” You can identify forward-looking statements by the use of words such as “expect,” “anticipate,” “estimate,” “may,” “will,” “should,” “intend,” “believe,” and similar expressions. Although we believe the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risk and we can give no assurances that our expectations will prove to be correct. Actual results could differ from those described in this Form 10-Q because of numerous factors, many of which are beyond our control. We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect actual outcomes. Overview We are a development stage company and reported net losses of approximately $269,000 and $217,000 for the three months ended March 31, 2023 and 2022, respectively. We had current assets of approximately $80,000 and current liabilities of $524,000 as of March 31, 2023. As of December 31, 2022, our current assets and current liabilities were approximately $59,000 and $65,000, respectively. We have prepared our financial statements for the three months ended March 31, 2023 assuming that we will continue as a going concern. Our continuation as a going concern is dependent upon NewStem’s ability to successfully develop and commercialize its products, improving our profitability and the continuing financial support from our shareholders as well as. Our sources of capital in the past have included the sale of equity securities, which include common stock sold in private transactions, large alternative minimum tax refunds, and related party debt. NewStem is a development stage Israeli biotech limited liability company focused on pioneering intellectual property related to haploid human embryonic stem cells for the development of personalized diagnostics and therapeutics for genetic and epigenetic diseases. NewStem has incurred losses related to in process research and development since inception and the Company records our percentage allocation of these net losses as incurred. We have included the condensed financial statements of NewStem as an exhibit to this Form 10-Q. RESULTS OF OPERATIONS The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto and other financial information appearing elsewhere in this Form 10-Q. In the discussion below, general and administrative expenses are referred to as “G&A expenses”. Three Months Ended March 31, 2023 2022 Change Operating expenses: G&A expenses $ 164,792 $ 138,956 $ 25,836 Contra expenses - legal fees - (310,000 ) 310,000 Total operating expenses 164,792 (171,044 ) 335,836 Loss from operations (164,792 ) 171,044 335,836 Interest expense 7,313 1,605 5,708 Net loss before equity in net loss of equity method investees (172,105 ) 169,439 (341,544 ) Equity in net loss of equity method investees (96,716 ) (386,903 ) 290,187 Net loss $ (268,821 ) $ (217,464 ) $ (51,357 ) We are a holding company whose primary assets are our ownership of equity interests in NewStem and NetCo. We conduct no other business and as a result, we have no revenue or cost of revenue. The Company incurs G&A expenses primarily related to professional fees and insurance. We incurred G&A expenses of approximately $165,000 and $139,000 for the three months ended March 31, 2023 and 2022, respectively. Specifically, professional fees increased by approximately $60,000 in the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. Our increase in G&A expenses relates primarily to professional fees incurred in the audit of our financial statements for the year ended December 31, 2022 and, in the preparation, and filing of our initial Form 10Q filed for the quarter ended September 30, 2022. 15 Stock compensation expense, included in G&A expenses, decreased by approximately $34,000 in the three months ended March 31, 2023 as compared to the three months ended March 31, 2022 due to a smaller number of options awarded in the current period as compared to the prior period. During the three months ended March 31, 2022 we recorded a contra expense of $310,000 which is comprised of funds from a litigation funding agreement. This agreement was signed during the first quarter of 2022 with Omni Bridgeway to fund our arbitration against our 50% joint venture partner, C.P. Group. This is a nonrecourse agreement and the Company has no obligation to repay any funds received under the agreement. In the event of a favorable outcome, Omni Bridgeway would recover disbursed funding as part of their investment return. As part of that funding arrangement, Omni Bridgeway agreed to reimburse NovelStem $310,000 which was comprised of $140,000 for reimbursement of previously incurred legal expenses and $170,000 for working capital needs including previously incurred general and administrative costs. There was no contra expense in the three months ended March 31, 2023. The Company has recorded no income tax expense as we have incurred operating losses and all deferred tax assets are fully offset by an income tax valuation allowance. We reported net losses from equity method investees in all periods presented. The net losses reported for the three months ended March 31, 2023 included net income of $7,875 from NetCo which was offset by net loss of $104,591 from NewStem. The net losses reported for the three months ended March 31, 2022 were fully comprised of net losses from NewStem. Liquidity and Capital Resources We have never paid dividends on our common stock. Our present policy is to apply cash to investments in product development at NewStem, acquisitions or expansion; consequently, we do not expect to pay dividends on common stock in the foreseeable future. We expect to continue to incur greater expenses in the near future as we expand our business or enter into strategic partnerships. We expect our G&A expenses to remain consistent in the near term as we have expanded our finance and administrative staff and incurred additional costs related to being a reporting act company, including directors’ and officers’ insurance and increased professional fees, which should all now be normalized for our current operations. The Company will need to obtain additional funds to continue its operations. Management’s plans with regard to these matters include additional financing and fundraising until its equity investment in NewStem is profitable. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStem will become profitable. In May 2022, the Company entered into an agreement with Jan Loeb, our Executive Chairman and Jerry Wolasky, a member of the Board, which was amended in July 2022, to borrow up to an aggregate of $600,000 for working capital needs. This agreement provides for funding through January 31, 2024, provides for interest at a rate of 8% per annum, increased to 10% per annum for advances subsequent to November 11, 2022, and matures the earlier of January 31, 2024 or twenty months from the date of the first funded amount unless the lenders agree to extend the due date at that time. As of the date of this Form 10-Q, the Company has drawn $350,000 pursuant to the aforementioned agreement. On May 5, 2023 the Company entered into a financing agreement with a shareholder to borrow $300,000 consisting of advances of $150,000 in May 2023 and $150,000 in October 2023. This agreement bears no interest and matures May 5, 2025. 16 ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK This section is not applicable. ITEM 4. CONTROLS AND PROCEDURES Our Principal Executive Officer and Chief Financial Officer conducted an evaluation of our controls and procedures. We have identified material weaknesses in our internal control and procedures and internal control over financial reporting. If not remediated, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common stock. Maintaining effective internal control over financial reporting and effective disclosure controls and procedures are necessary for us to produce reliable financial statements. We have re-evaluated our internal control over financial reporting and our disclosure controls and procedures and concluded that they were not effective as of March 31, 2023 and we concluded there was a material weakness in the design of our internal control over financial reporting. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses identified included insufficient resources to employ proper segregation of duties over the processing of transactions and financial reporting. Changes in Internal Control Over Financial Reporting There was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. PART II ITEM 1. LEGAL PROCEEDINGS Netco owns all rights in all media to the NetForce intellectual property including film, television, and video games. Consistent with our contractual and statutory rights, NovelStem is intent on commercially exploiting the full array of media rights relating to Net Force. We have initiated an arbitration proceeding against our 50% partner in Netco, C.P. Group, in an effort to maximize the total potential value to be derived from fully utilizing the Netco intellectual property across video games, streaming, entertainment, digital media, merchandising and other ancillary markets. Arbitration proceedings for the joint owners of NetCo began in July 2022. To fund efforts to maximize the value of Netco, NovelStem has secured non-recourse litigation funding. Arbitration proceedings for the joint owners of NetCo concluded during 2022 with final briefs being filed in January 2023. On May 10, 2023, the arbitrator ordered a final briefing from all parties to be filed by May 30, 2023. At this time, the arbitrator indicated that a decision will be rendered within 30 days of the filing of these final briefings. ITEM 1A. RISK FACTORS We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS (a) Not applicable. (b) Not applicable. (c) Not applicable. ITEM 3. DEFAULTS UPON SENIOR SECURITIES Not applicable. ITEM 4. MINE SAFETY DISCLOSURES Not applicable. ITEM 5. OTHER INFORMATION None. ITEM 6. EXHIBITS #31.1 Certification of Principal Executive Officer and Executive Chairman pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. #31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. #32.1 Certification of Principal Executive Officer and Executive Chairman pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. #32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. #33.1 Condensed Financial Statements of NewStem Ltd. as of and for the nine months ended March 31, 2023 #101.1 The following financial statements from NovelStem International Corp.’s Form 10-Q for the quarter ended March 31, 2023, filed on May 12, 2023, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Balance Sheets, (ii) Condensed Statements of Operations, (iii) Condensed Statements of Changes in Shareholders’ Equity, (iv) Condensed Statements of Cash Flows and (v) Notes to Condensed Financial Statements, tagged as blocks of text. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). # This exhibit is filed or furnished herewith. 17 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized. NOVELSTEM INTERNATIONAL CORP. Date: May 12, 2023 By: /s/ Jan Loeb Name: Jan Loeb Title: Executive Chairman 18